The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia

BJU International

Volumn 93, Issue SUPPL. 1, 2004, Pages 21-26

  Roehrborn, C G ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ALGORITHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; HUMAN; MALE; META ANALYSIS; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; REVIEW; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING; URINARY TRACT; URINE RETENTION;

ALGORITHMS; HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME; URINARY RETENTION;

EID: 1642369033     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2003.04636.x     Document Type: Review

References (20)

1. Roehrborn C, McConnell J. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In Walsh P, Retik A, Vaughan E, Wein AJ eds, Campbell's Urology, 8th edn. Philadelphia: Saunders, 2002: 1297-336
2. Girman CJ, Jacobsen SJ, Tsukamoto T et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998; 51: 428-36
3. Girman CJ, Jacobsen SJ, Rhodes T et al. Association of health-related quality of life and benign prostatic enlargement. Eur Urol 1999; 35: 277-84
4. Anderson JB, Roehrborn CG, Schalken JA et al. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol 2001; 39: 390-9
5. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405
6. Sech SM, Montoya JD, Bernier PA et al. The so-called 'placebo effect' in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring. Urology 1998; 51: 242-50
7. Roehrborn CG, Boyle P, Gould AL et al. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999; 53: 581-9
8. Rhodes T, Girman CJ, Jacobsen SJ et al. Longitudinal prostate growth rates during 5 years in randomly selected community men 40-79 years old. J Urol 1999; 161: 1174-9
9. Roehrborn CG, McConnell J, Bonilla J et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000; 163: 13-20
10. Roehrborn CG, Boyle P, Nickel JC. PSA is a significant predictor of objective parameters in men at risk for BPH progression. J Urol 2003; 169: A1362
11. Wright EJ, Fang J, Metter EJ et al. Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. J Urol 2002; 167: 2484-8
12. Roehrborn CG, Boyle P, Bergner D et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a 4-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 1999; 54: 662-9
13. Bruskewitz R, Girman CJ, Fowler J et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 1999; 54: 670-8
14. Roehrborn CG, McConnell JD, Lieber M et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999; 53: 473-80
15. Roehrborn CG, Malice M, Cook TJ et al. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001; 58: 210-6
16. Boyle P, Roehrborn C, Gould L. Baseline serum PSA levels predict degree of symptom improvement following therapy of BPH with finasteride. J Urol 1997; 157: A134
17. Kaplan S, Garvin D, Gilhooly P et al. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. Urology 2000; 56: 610-6
18. Barkin J, Guimaraes M, Jacobi G et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 2003; 44: 461-6
19. Albertsen PC, Pellissier JM, Lowe FC et al. Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study. Clin Ther 1999; 21: 1006-24
20. Roehrborn CG, Boyle P, Nickel JC et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41